The IQVIA Institute for Human Data Science

Evidence-based insights for healthcare

The IQVIA Institute for Human Data Science contributes to the advancement of human health globally through timely research, insightful analysis and scientific expertise applied to granular non-identified patient-level data.
Subscribe to the IQVIA Institute
Be among the first to hear about research and activities

Latest Reports

Download the latest Institute reports

Video Research Brief

The Global Use of Medicines Outlook Through 2029

Hear from the report authors as they share key findings on global medicine use and rising spending, driven by innovative therapies and widening access. This report analyzes global trends and provides insights for stakeholders through 2029.

Video Research Brief

Designing Oncology Clinical Development Programs in the Era of the IRA

Watch our eminent panelists share their perspectives on the impact of the IRA on oncology drug development strategy, the implications for clinical development stakeholders, and approaches to mitigating unintended consequences for innovation at the IQVIA Institute’s Pre-ASCO Symposium 2025.

Video Research Brief

Global Oncology Trends 2025

The Global Oncology Trends 2025 report explores novel cancer therapies, rising expenditures, and access disparities. It highlights trends in ADCs, radioligand therapies, CAR-T, and spending projections through 2029.

View all of the IQVIA Institute's Upcoming and On-Demand Events

Trending

Annual Reports on Latest Trends

The Global Use of Medicines

Learn about spending and usage of medicines in the past year and outlook to the future, globally and across specific therapy areas and countries.

Global Trends in R&D

Discover trends in drug approvals and launches, pipeline activity, and data on clinical trial activity.

The Use of Medicines in the U.S.

Examine the state of the U.S. health system, medicine usage, drug pricing, and costs for patients.

Global Oncology Trends

Explore research and development in oncology and the progress being made to improve representativeness of race and ethnicity in clinical trial populations.

Contact Us